By Sam Young In 2023, the world of psychedelic research and therapy witnessed a paradigm shift, marking an era where ancient wisdom and modern science converge. This year, Australia emerged as [...]
Image credit: Michael Garfield and Alex Grey artworks digitally combined By Melissa Warner and Jasmine Blom 5-MeO-DMT is a unique and compelling member of the modern psychedelic pharmacopoeia. [...]
Exploring the PRISM and DanceWize partnership By Stephanie Tzanetis Psychedelic assisted-psychotherapy (PAP), as the name indicates, is a therapy session aided by psychedelic compounds. By [...]
By Josh Miosku & Melissa Warner A cultural and scientific exploration of a little known non-traditional psychedelic. Salvia divinorum, Latin for sage of the diviners, is a perennial plant of [...]
Media Release: 16th December 2021 TGA Rescheduling of Psilocybin and MDMA: Delegate’s Final Decision On December 15th, the Therapeutic Goods Administration (TGA) announced the [...]
Media Release: 1st of October 2021 TGA Rescheduling of Psilocybin and MDMA Independent Expert Review Panel Report Yesterday, the Australian Therapeutic Goods Administration (TGA) published [...]
MDMA Research Update The Perth MDMA-assisted psychotherapy trial has received ethics approval. With the support of PRISM donations, the Perth site has installed a Schedule 9 safe for secure [...]
Around the world there is a rapidly growing body of scientific evidence suggesting that psychedelic drugs are safe and highly effective when used under medical supervision. Why did promising [...]
Paul Liknaitzky hopes for “rigorous research that is neither biased toward panacea thinking, nor ignorant of the best-practice track record and literature to date”. “This field has suffered from [...]
Nigel Strauss and Paul Liknaitzky contend that, at least initially, all training should take place within clinical trials overseen by experienced international clinicians and be limited to [...]
While the anecdotal accounts are compelling, significant questions remain around how microdosing works, and how much of the reported benefits are due to pharmacological effects, rather than [...]
People who use drugs understand drugs and drug use in ways that are often different to the way knowledge of drug use is constructed within the dominant medico-legal discourse. Their experiences [...]
There’s a landmark project underway in Melbourne to find out whether psilocybin – the hallucinogenic compound in magic mushrooms – can be used to improve end-of-life [...]
Dr Bright said Australia had the opportunity to “scale up”, with bigger trials ensuring more therapists were trained so when MDMA was given the green light in the US, the safety data [...]
People who use drugs understand drugs and drug use in ways that are often different to the way knowledge of drug use is constructed within the dominant medico-legal discourse. Their experiences [...]
There is increasing evidence that psychedelic-assisted psychotherapy is effective for a range of psychological conditions. There are likely numerous mechanisms of action that contribute to these [...]
…Earlier this year PRISM obtained approval to give psilocybin to 30 terminally ill patients at St Vincent’s Hospital in Melbourne to ease their end-of-life anxiety and crisis. It’s a phase [...]
Psychedelic drugs could revolutionise current treatment options for mental health conditions as growing evidence demonstrates the profound effects of Psilocybin and MDMA. Over 100 studies in the [...]
“After one dose of psilocybin, death anxiety declined…nothing in psychology comes close to that!”, psychiatrist Margaret Ross. St. Vincent’s hospital will undergo novel trials involving [...]
Psychedelics are a broad category of drugs that can produce profound changes in consciousness. “Magic mushrooms”, containing psilocybin, have been used by some indigenous communities for at least [...]
The correlation between mental health conditions and technology suggests that our increased screen time is contributing to poorer overall wellbeing and even addictive symptoms. A new kind of [...]
Psilocybin, the psychoactive compound from magic mushrooms, is being used to treat depression and anxiety in terminally ill patients in a new trial at Melbourne’s St Vincent’s Hospital.
International research is increasingly demonstrating that psychedelic-assisted psychotherapy can enhance psychotherapeutic outcomes and be effective for some treatment-refractory mental [...]
Prestigious international institutions have initiated robust psychedelic research programs. Does Australia risk being left behind if it doesn’t do the same?
New research published in the Australian Psychologist Journal claims Australia is missing out on the benefits of using psychedelic drugs to treat a range of mental health illnesses.
On 9th April 2018 The Project (Channel Ten) interviewed PRISM co-founders Dr Stephen Bright and Steve McDonald about the need for Australia to embrace formal research into psychedelic medicines.
In a press release dated 26 August 2017, the Multidisciplinary Association for Psychedelic Studies (MAPS) announced that the US Food and Drug Administration has granted ‘Breakthrough [...]